Access to Allogeneic Hematopoietic Cell Transplant for Patients with Hematologic Malignancies in Oregon

Danielle Brouillard(Oregon Health & Science University), Eneida R. Nemecek(Oregon Health & Science University), Brandon Hayes‐Lattin(Oregon Health & Science University), Arpita P Gandhi(Oregon Health & Science University), Jessica Leonard(Oregon Health & Science University), Jennifer N. Saultz(Oregon Health & Science University), Gabrielle Meyers(Oregon Health & Science University), Staci Williamson(Oregon Health & Science University), Rachel J. Cook(Oregon Health & Science University), Jessie Myers(Oregon Health & Science University), Yazan Migdady(University of Florida), Richard T. Maziarz(Oregon Health & Science University), Laura F. Newell(University of Washington), Brittany O'Barr(Oregon Health & Science University), LeeAnn Kamerman(Oregon Health & Science University), Maryam Rezaie(Oregon Health & Science University), Amrita Desai(Oregon Health & Science University)
Transplantation and Cellular Therapy
February 1, 2024
10.1016/j.jtct.2023.12.604
Cited by 0

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577